Blood test suggests preeclampsia risk using RNA

Preeclampsia can cause many pregnancy complications including death, but it can be difficult to perceive Early gestation. A new blood test can help doctors identify those who have the risk of developing a few months before the start of the symptoms.

“We can reduce high risk in 4 pregnancies in pregnancy, and it’s a great step,” he says Maneeesh god In Mirvie, launch of california health.

Preaclampsia is a hypertensive type of pregnancy disorder (HDP) when something happens – scientists don’t sure what happens in the development of placenta. This has high blood pressure that causes cardiovascular diseases, the damage of the organ, seizures and death. It can also damage the fetus being developed.

PreekLampsia and other HDPs can be difficult to catch, however, because symptoms usually do not usually appear until at least 20 weeks during pregnancy. Sometimes signs are not selected. And Placental development monitoring It is hard to take a sample of the organ because it is very invasive.

The new blood test is non-invasive, and RNA markers use someone to predict a HDP. Specifically, tests are based on certain genes, including Dad2 and Cd163has previously been associated with HDP. Researchers wanted to see whether they can detect this supervision in blood samples.

The validation of more than 9000 pregnant is as follows that the test was able to determine the accuracy of 99 percent, which had not experienced the genes who had already had the risks of preklampsia or other HDP. Approximately a quarter of the participants, HDP risk risk factors did not supervise genes.

People in certain demographics – for example, with high pre-pressure or preklampsia family history, says that they have a higher risk of developing condition Morten Rasmussen In Mirvie. But for many, it seems to come from the blue.

Someone have a high risk of preklampsia, they can take precautions to avoid. Ordinary interventions is to take drugs like aspirin, a Mediterranean diet And to control hypertension daily.

However, the new test looked at only 17.5 weeks and 22 weeks during pregnancy. “It is best to start aspirin before 16 weeks,” he says Kathryn gray Seattle at Washington University. “So we’ve already lost that window when most people would get the results of this test.”

Mirvie is now intending to take a commercial blood test. When it is on the market, the team will use drugs to develop drugs such as genes like other scientists Dad2. Such molecular point “gives a better chance to show treatment,” says Rasmussen.

Gray would also like researchers to use Mirvie’s RNA data bank to deepen the genes behind the risks of preechlampsia for certain people. The tightening of the search profile can help reduce the cost of the test to make it cheaper for more people.